Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma
University of Heidelberg Medical Center
University of Heidelberg Medical Center
Pfizer
Centre Hospitalier Régional d'Orléans
Arab American University (Palestine)
Celgene
Thomas Jefferson University
Cedars-Sinai Medical Center
Cyteir Therapeutics, Inc.
Astex Pharmaceuticals, Inc.
Cedars-Sinai Medical Center
Kyowa Kirin Co., Ltd.
National Cancer Institute (NCI)
Celgene
Novartis
University of California, San Francisco
Zhongnan Hospital
Teva Branded Pharmaceutical Products R&D, Inc.
Amgen
Icahn School of Medicine at Mount Sinai
Rigshospitalet, Denmark
Celgene
Kartos Therapeutics, Inc.
GlaxoSmithKline
Merck Sharp & Dohme LLC
University Hospital, Lille
Icahn School of Medicine at Mount Sinai
Jonsson Comprehensive Cancer Center
Novartis
Celgene
GlaxoSmithKline
InSightec
LEO Pharma
AbbVie
Amgen
European Organisation for Research and Treatment of Cancer - EORTC
Wake Forest University Health Sciences
OHSU Knight Cancer Institute
University of Louisville
Vanderbilt University Medical Center
Ohio State University Comprehensive Cancer Center
University of Kansas Medical Center
Genentech, Inc.
Leap Therapeutics, Inc.
Sandoz
University of Arkansas
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Valerio Therapeutics
National Cancer Institute (NCI)
Erasmus Medical Center